Skip to content

Depression research published in 2025

Page 18 of 39: studies 341 to 360 of 761, newest first. Back to the depression overview

Studies

Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.

ACS Medicinal Chemistry Letters June 12, 2025 Robert B. Kargbo 1 citation

Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric...

The pattern of dissociative symptoms differs between post-traumatic stress disorder and first esketamine administration for treatment-resistant depression.

Journal of Affective Disorders June 12, 2025 David Williamson, Linda Williamson, Viola Vaccarino et al. 2 citations

Dissociative symptoms are commonly observed in a substantial minority of patients with Post-Traumatic Stress Disorder (PTSD) and during the first administration of esketamine for the treatment of Treatment-Resistant Depression (TRD). We examine differences in the number and pattern of dissociative symptoms (depersonalization, derealization, dissociative amnesia, identity fragmentation) reported...

DOI: 10.1016/j.jad.2025.119632 (opens in new tab) Full text (opens in new tab) Nmda receptor antagonists Posttraumatic Stress Treatment resistant depression +6

Impacts of the Mindfulness Meditation Mobile App Calm on Undergraduate Students' Sleep and Emotional State: Pilot Randomized Controlled Trial.

JMIR Formative Research June 11, 2025 Tovan Lew, Natnaiel M Dubale, Erik Doose et al. 3 citations

Undergraduate students frequently experience negative emotional states and sleep quality, which is believed to have worsened following the COVID-19 pandemic. This study piloted the use of a popular mobile mindfulness app (Calm) as a potential intervention to improve state depression, anxiety, stress, and sleep quality in undergraduate students attending a Canadian university, following the...

Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.

Metabolic Brain Disease June 11, 2025 Daniel do Nascimento Sousa, Monique de Azevedo, Maria Lucília Santos et al. 5 citations

Ayahuasca (Aya) is an Amazonian beverage traditionally used as medicine by Indigenous people in South America to treat various illnesses and have shown a potential to treat depression. This study aimed to investigate the antidepressant effects of fluoxetine, Aya and N, N dimethyl tryptamine (DMT), a component of the beverage, focusing on the modulation of inflammatory serum cytokine profiles...

Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders

Psychedelics June 10, 2025 Stephen Ross

Professor Stephen Ross is a prominent faculty member in the Departments of Psychiatry and Child and Adolescent Psychiatry at the New York University (NYU) Grossman School of Medicine who has transformed the landscape of psychedelic research since 2006. In this Genomic Press Interview, Dr. Ross reveals how as co-director of the NYU Langone Center for Psychedelic Medicine and director of its...

Unveiling the Anti-Inflammatory Effects of Antidepressants: A Systematic Review of Human Studies over the Last Decade.

Pharmaceuticals June 10, 2025 Layla Bleibel, Paulina Sokołowska, Gabriela Henrykowska et al. 18 citations

Background/Objectives: Depression ranks among the most prevalent mental health conditions globally, marked by a variety of symptoms that frequently cause significant emotional distress and impairment in individuals, alongside a high recurrence rate. The predominant approach to treating depression revolves around monoamine theory, utilizing SSRIs and SNRIs, with Esketamine emerging as a...

Prophylactic esketamine for postpartum depression after cesarean section: a systematic review and meta-analysis.

Journal of Affective Disorders June 10, 2025 Haibin Shi, Caihong Zheng, Bin Zhu 5 citations

According to recent research, esketamine may reduce the incidence of postpartum depression (PPD) risk following cesarean delivery. To further assess this potential benefit, a meta-analysis was conducted. Embase, Web of Science, the Cochrane Library, and PubMed were searched from inception through March 2025. Meta-analysis was performed using random-effects models to calculate risk ratios (RRs)...

DOI: 10.1016/j.jad.2025.119631 (opens in new tab) Full text (opens in new tab) Meta-analysis Postpartum depression ppd Postnatal depression Cesarean section c-section +4

Efficacy and Moderators of Mindfulness-Based Cognitive Therapy (MBCT) in ‘Difficult to Treat’ Depression: Protocol for a Systematic Review and Individual Patient Data Meta-Analysis of Randomised Controlled Trials

medRxiv June 9, 2025 Thorsten Barnhofer, Maria Niemi, Johannes Michalak et al. preprint

ABSTRACT: Introduction: About 30% of depressed patients suffer from a protracted course in which the disorder continues to cause significant burden despite treatment efforts. While originally developed for relapse prevention, Mindfulness-Based Cognitive Therapy (MBCT) has increasingly been investigated in depressed patients with such ‘difficult-to-treat’ courses. This is a protocol for an...

The Impact of Mindfulness Programmes on Anxiety, Depression and Stress During Pregnancy: A Systematic Review and Meta-Analysis.

Healthcare June 9, 2025 María Dolores Vázquez-Lara, Azahara Ruger-Navarrete, Samia Mohamed-Abdel-Lah et al. 2 citations

Mental health problems that can appear in women during pregnancy include fear, anxiety, feelings of vulnerability, stress, and depression. Mindfulness (MF) is a specific meditation technique that can help during treatment for prenatal mood disorders, emotional distress, and psychological strains. The aim of this study is to determine the effectiveness of a specific meditation approach in women...

DOI: 10.3390/healthcare13121378 (opens in new tab) Full text (opens in new tab) Psychological stress Mindfulness interventions Expectant mothers Well-being throughout pregnancy +4

‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression

PsyArXiv June 9, 2025 3 citations preprint

Importance: Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding. This effect positively biases results when PAT trials are compared against truly blinded trials. Objective: This pre-registered meta-analysis investigated the comparative efficacy of PAT and open-label traditional antidepressants (tAD; such as SSRIs and SNRIs) for the treatment of major depression....

DOI: 10.31234/osf.io/vhs4a_v1 (opens in new tab) Psychedelic therapy Psychedelic treatment Psychedelics Hallucinogen therapy +14

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.

Journal of comparative effectiveness research June 9, 2025 Kristin Clemens, Amanda Teeple, Benoit Rive et al.

Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK NS + OAD) versus quetiapine extended release plus an oral antidepressant (QTP XR + OAD) among adults with treatment-resistant depression (TRD). Materials & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK NS + OAD and QTP XR + OAD from the perspective of a US...

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study.

Journal of Affective Disorders June 9, 2025 Sara Ellis, Catherine Bostian, Anna Donnelly et al. 3 citations

One-third of Veterans with major depressive disorder suffer from treatment-resistant depression (TRD). This is the first study to evaluate the long-term outcomes of psilocybin in Veterans with severe TRD. This paper presents 12-month results from an open-label pilot study assessing the effects of 25 mg psilocybin in Veterans with severe TRD, defined as a major depressive episode failing to...

Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 7, 2025 Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała 5 citations

Treatment-resistant depression (TRD) remains a challenge, with many patients unresponsive to standard antidepressants. NN-dimethyltryptamine (DMT), a fast-acting psychedelic, offers potential benefits due to its rapid onset and short duration. This review, registered with the Open Science Framework (DOI: 10.17605/OSF.IO/6D9WC), summarizes the safety and tolerability of DMT in early-phase...

DOI: 10.1016/j.pnpbp.2025.111419 (opens in new tab) Full text (opens in new tab) Nn-Dimethyltryptamine DMT Systematic review Treatment resistant depression Psychedelics hallucinogens +4

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.

The International Journal of Neuropsychopharmacology June 6, 2025 Naim Zaki, Li Nancy Chen, Rosanne Lane et al. 32 citations

The rates of relapse and suicide risk are higher in treatment-resistant depression (TRD) vs non-treatment-resistant major depressive disorder. Even among patients with TRD who initially respond, the majority (70%) relapse within 6 months. To evaluate the long-term safety and efficacy of esketamine nasal spray, combined with an oral antidepressant, in patients with TRD. Phase 3, open-label,...

Acute effects of intranasal esketamine application on thalamic structures in healthy individuals.

The International Journal of Neuropsychopharmacology June 6, 2025 Benjamin Spurny-Dworak, Thomas Liebe, Samantha Graf et al. 2 citations

The N-methyl-D-aspartate receptor antagonist ketamine has found broad application in the field of psychiatry. Due to its rapid antidepressant and anti-suicidal properties, it is used as a treatment for major depressive disorder. Furthermore, ketamine evokes dissociative and psychotropic states, which allows the modeling of schizophrenic symptoms. The thalamus, a main target for ketamine's...

Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder.

Journal of Psychopharmacology June 5, 2025 Ben Beaglehole, Paul Glue, Shona Neehoff et al. 19 citations

We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. All participants from the original study were eligible...

Effects of online mindfulness-based stress reduction training on depression and anxiety symptoms among psychiatric healthcare workers in a randomized controlled trial: the mediating role of emotional suppression.

BMC Psychiatry June 4, 2025 Yuekun Wu, Yue Ban, Guoliang Pan et al. 6 citations

Psychiatric healthcare workers experience prolonged exposure to psychological trauma and negative emotions, which ultimately predisposes them to mental health issues. The effectiveness of online mindfulness-based stress reduction training on depression and anxiety symptoms among psychiatric healthcare workers (HCWs) and the possible mechanisms that benefit these outcomes remain unclear. This...

DOI: 10.1186/s12888-025-06967-1 (opens in new tab) Full text (opens in new tab) Meditation Emotional suppression Mediator Online mindfulness-based training +10

Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial.

Med June 4, 2025 Felix Müller, Hannes Zaczek, Anna M Becker et al. 21 citations

This trial aimed to assess the efficacy of lysergic acid diethylamide (LSD)-assisted therapy in patients with moderate-to-severe major depressive disorder. This was a randomized, parallel, double-blind, low-dose controlled trial (Clinicaltrials.gov: NCT03866252). Patients were randomly assigned in a 1:1 ratio to receive supportive psychotherapy and either 100 μg + 200 μg LSD or 25 μg + 25 μg...

Modulation of ER Stress and Inflammation by S-Ketamine, R-Ketamine, and Their Metabolites in Human Microglial Cells: Insights into Novel Targets for Depression Therapy.

Cells June 3, 2025 Marta Jóźwiak-Bębenista, Anna Wiktorowska-Owczarek, Małgorzata Siatkowska et al. 4 citations

Despite affecting millions worldwide, major depressive disorder (MDD) remains a therapeutic challenge, with approximately one-third of patients failing to respond to standard treatments. The need for innovative, molecularly driven therapies has turned attention to ketamine and its enantiomers. While S-ketamine is clinically approved for treatment-resistant depression (TRD), it has various...

Cardiovascular Effects of Non-Selective Monoamine Oxidase Inhibitors and Intranasal Esketamine Combination in Depression - A Quasi-Experimental Design with Bayesian Analyses.

Pharmacopsychiatry June 2, 2025 Ludovic C Dormegny-Jeanjean, Suzie Lenoir, Ilia Humbert et al. 1 citation

Ketamine and esketamine (ESK) offer new treatment options for resistant depression. Unlike traditional antidepressants, they can be used in combination with non-selective monoamine oxidase inhibitors (NS-MAOI) without the risk of serotonergic syndrome. However, potential sympathomimetic synergy may lead to elevated blood pressure (BP). This series investigates whether cardiovascular parameters...

DOI: 10.1055/a-2590-3469 (opens in new tab) Full text (opens in new tab) Depression Antidepressants Mental health Medical research +1